Edwards Lifesciences Gets European OK on Therapy

Edwards Lifesciences Corp. said Thursday that it has won approval from European regulators to sell its next-generation treatment for abdominal aortic aneurysms, which are potentially life-threatening.

The product, called Lifepath AAA Endovascular Graft System, is a less-invasive treatment for the condition, which involves a weakening and ballooning of the wall of the aorta, the body’s main circulatory channel.

Irvine-based Edwards said it will begin commercial roll-out of the new product immediately.

The company’s stock edged up 27 cents to $22.32 Thursday on the New York Stock Exchange.